Editas Medicine Inc

8EM

Company Profile

  • Business description

    Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

  • Contact

    11 Hurley Street
    CambridgeMA02141
    USA

    T: +1 617 401-9000

    E: [email protected]

    https://www.editasmedicine.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    226

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,777.9050.80-0.58%
CAC 407,794.6527.940.36%
DAX 4024,275.3268.410.28%
Dow JONES (US)44,240.76165.60-0.37%
FTSE 1008,868.3114.130.16%
HKSE23,876.70271.37-1.12%
NASDAQ20,418.465.950.03%
Nikkei 22539,821.28132.470.33%
NZX 50 Index12,768.6190.41-0.70%
S&P 5006,225.524.46-0.07%
S&P/ASX 2008,538.6052.10-0.61%
SSE Composite Index3,493.054.43-0.13%

Market Movers